Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Erratum for Sekaggya-Wiltshire et al., "Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?"

Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P.

Antimicrob Agents Chemother. 2020 Mar 24;64(4). pii: e00315-20. doi: 10.1128/AAC.00315-20. Print 2020 Mar 24. No abstract available.

PMID:
32209563
2.
3.

A systematic review and meta-analysis of first-line tuberculosis drug concentrations and treatment outcomes.

Perumal R, Naidoo K, Naidoo A, Ramachandran G, Requena-Mendez A, Sekaggya-Wiltshire C, Mpagama SG, Matteelli A, Fehr J, Heysell SK, Padayatchi N.

Int J Tuberc Lung Dis. 2020 Jan 1;24(1):48-64. doi: 10.5588/ijtld.19.0025.

PMID:
32005307
4.

A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa.

Semakula JR, Mouton JP, Jorgensen A, Hutchinson C, Allie S, Semakula L, French N, Lamorde M, Toh CH, Blockman M, Sekaggya-Wiltshire C, Waitt C, Pirmohamed M, Cohen K.

PLoS One. 2020 Jan 29;15(1):e0227458. doi: 10.1371/journal.pone.0227458. eCollection 2020.

5.

Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: a case control study.

Buzibye A, Musaazi J, von Braun A, Nanzigu S, Sekaggya-Wiltshire C, Kambugu A, Fehr J, Lamorde M, Gutteck U, Muller D, Sowinski S, Reynolds SJ, Castelnuovo B.

AIDS Res Ther. 2019 Dec 6;16(1):39. doi: 10.1186/s12981-019-0255-x.

6.

Pharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosis.

Sekaggya-Wiltshire C, Dooley KE.

Expert Opin Drug Metab Toxicol. 2019 Aug;15(8):615-618. doi: 10.1080/17425255.2019.1648432. Epub 2019 Jul 30. No abstract available.

PMID:
31339806
7.

Sustained positive impact on tuberculosis treatment outcomes of TB-HIV integrated care in Uganda.

Musaazi J, Sekaggya-Wiltshire C, Kiragga AN, Kalule I, Reynolds SJ, Manabe YC, Castelnuovo B.

Int J Tuberc Lung Dis. 2019 Apr 1;23(4):514-521. doi: 10.5588/ijtld.18.0306.

PMID:
31064632
8.

Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?

Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02174-18. doi: 10.1128/AAC.02174-18. Print 2019 Jun. Erratum in: Antimicrob Agents Chemother. 2020 Mar 24;64(4):.

9.

A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients.

Kaboggoza JP, Wang X, Neary M, Ayuso P, Sekaggya-Wiltshire C, Nakalema S, Owen A, McClure M, Lamorde M, Boffito M.

Open Forum Infect Dis. 2019 Jan 16;6(2):ofz035. doi: 10.1093/ofid/ofz035. eCollection 2019 Feb. No abstract available.

10.

The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study.

Calcagno A, Cusato J, Sekaggya-Wiltshire C, von Braun A, Motta I, Turyasingura G, Castelnuovo B, Fehr J, Di Perri G, Lamorde M.

Clin Pharmacol Ther. 2019 Aug;106(2):450-457. doi: 10.1002/cpt.1403. Epub 2019 Mar 29.

PMID:
30779340
11.

Virological Outcome of Patients With HIV Drug Resistance Attending an Urban Outpatient Clinic in Uganda: A Need for Structured Adherence Counseling and Third-Line Treatment Options.

Baumann A, Musaazi J, Kambugu A, Kälin M, Weissberg D, Ssemwanga D, Fehr J, Castelnuovo B, Sekaggya-Wiltshire C, von Braun A.

J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):481-487. doi: 10.1097/QAI.0000000000001943.

PMID:
30633041
12.

Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland.

Bachmann N, von Braun A, Labhardt ND, Kadelka C, Günthard HF, Sekaggya-Wiltshire C, Castelnuovo B, Kambugu A, Lejone TI, Böni J, Yerly S, Perreau M, Klimkait T, Kouyos RD, Fehr J; Swiss HIV Cohort Study.

J Antimicrob Chemother. 2019 Feb 1;74(2):468-472. doi: 10.1093/jac/dky436.

PMID:
30476115
13.

Ten years of antiretroviral therapy: Incidences, patterns and risk factors of opportunistic infections in an urban Ugandan cohort.

Weissberg D, Mubiru F, Kambugu A, Fehr J, Kiragga A, von Braun A, Baumann A, Kaelin M, Sekaggya-Wiltshire C, Kamya M, Castelnuovo B.

PLoS One. 2018 Nov 1;13(11):e0206796. doi: 10.1371/journal.pone.0206796. eCollection 2018.

14.

High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment.

von Braun A, Castelnuovo B, Ledergerber B, Cusato J, Buzibye A, Kambugu A, Fehr J, Calcagno A, Lamorde M, Sekaggya-Wiltshire C.

J Antimicrob Chemother. 2019 Jan 1;74(1):135-138. doi: 10.1093/jac/dky379.

PMID:
30239753
15.

Comparison of Löwenstein-Jensen and BACTEC MGIT 960 culture for Mycobacterium tuberculosis in people living with HIV.

Hongler J, Musaazi J, Ledergerber B, Eberhard N, Sekaggya-Wiltshire C, Keller PM, Fehr J, Castelnuovo B.

HIV Med. 2018 Oct;19(9):654-661. doi: 10.1111/hiv.12635. Epub 2018 Jul 3.

PMID:
29971898
16.

HIV-1 Drug Resistance Among Ugandan Adults Attending an Urban Out-Patient Clinic.

von Braun A, Sekaggya-Wiltshire C, Bachmann N, Ssemwanga D, Scherrer AU, Nanyonjo M, Kapaata A, Kaleebu P, Günthard HF, Castelnuovo B, Fehr J, Kambugu A.

J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):566-573. doi: 10.1097/QAI.0000000000001717.

17.

The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs.

Sekaggya-Wiltshire C, Lamorde M, Kiragga AN, Dooley KE, Kamya MR, Kambugu A, Fehr J, Manabe YC, Castelnuovo B.

Tuberculosis (Edinb). 2018 Jan;108:77-82. doi: 10.1016/j.tube.2017.11.004. Epub 2017 Nov 7. Review.

18.

Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.

Sekaggya-Wiltshire C, von Braun A, Lamorde M, Ledergerber B, Buzibye A, Henning L, Musaazi J, Gutteck U, Denti P, de Kock M, Jetter A, Byakika-Kibwika P, Eberhard N, Matovu J, Joloba M, Muller D, Manabe YC, Kamya MR, Corti N, Kambugu A, Castelnuovo B, Fehr JS.

Clin Infect Dis. 2018 Aug 16;67(5):708-716. doi: 10.1093/cid/ciy179.

19.

Detection of tuberculosis patterns in digital photographs of chest X-ray images using Deep Learning: feasibility study.

Becker AS, Blüthgen C, Phi van VD, Sekaggya-Wiltshire C, Castelnuovo B, Kambugu A, Fehr J, Frauenfelder T.

Int J Tuberc Lung Dis. 2018 Mar 1;22(3):328-335. doi: 10.5588/ijtld.17.0520.

PMID:
29471912
20.

Elevated Aspergillus-specific antibody levels among HIV infected Ugandans with pulmonary tuberculosis.

Kwizera R, Parkes-Ratanshi R, Page ID, Sekaggya-Wiltshire C, Musaazi J, Fehr J, Castelnuovo B, Kambugu A, Denning DW.

BMC Pulm Med. 2017 Nov 21;17(1):149. doi: 10.1186/s12890-017-0500-9.

21.

Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study.

Sekaggya-Wiltshire C, Castelnuovo B, von Braun A, Musaazi J, Muller D, Buzibye A, Gutteck U, Henning L, Ledergerber B, Corti N, Lamorde M, Fehr J, Kambugu A.

BMJ Open. 2017 Sep 18;7(9):e014679. doi: 10.1136/bmjopen-2016-014679.

22.

Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert™ MTB/RIF era: a cohort study.

Hermans SM, Babirye JA, Mbabazi O, Kakooza F, Colebunders R, Castelnuovo B, Sekaggya-Wiltshire C, Parkes-Ratanshi R, Manabe YC.

BMC Infect Dis. 2017 Jun 16;17(1):433. doi: 10.1186/s12879-017-2534-2.

23.

Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.

Sekaggya-Wiltshire C, von Braun A, Scherrer AU, Manabe YC, Buzibye A, Muller D, Ledergerber B, Gutteck U, Corti N, Kambugu A, Byakika-Kibwika P, Lamorde M, Castelnuovo B, Fehr J, Kamya MR.

J Antimicrob Chemother. 2017 Apr 1;72(4):1172-1177. doi: 10.1093/jac/dkw534.

24.

Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis.

von Braun A, Sekaggya-Wiltshire C, Scherrer AU, Magambo B, Kambugu A, Fehr J, Castelnuovo B.

AIDS Res Ther. 2017 Jan 5;14(1):1. doi: 10.1186/s12981-016-0128-5.

Supplemental Content

Loading ...
Support Center